Alzheimer's Disease Preclinical Research Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Preclinical Biomarker Discovery and Analysis Services

Inquiry

Identifying reliable biomarkers is critical for early diagnosis, monitoring disease progression, and evaluating therapeutic efficacy. Ace Therapeutics offers preclinical biomarker discovery and analysis services, leveraging cutting-edge technologies to uncover and validate biomarkers in AD animal models.

Why Biomarker Discovery Matters in Alzheimer's Research

Biomarkers serve as measurable indicators of biological processes, offering insights into disease mechanisms and therapeutic responses. In AD research, biomarkers are essential for

Detecting early pathological changes before cognitive symptoms appear.
Tracking disease progression in preclinical models.
Translating findings from animal studies to clinical trials.

Core Biomarker Discovery Services

Amyloid-Beta and Tau Biomarker Analysis

Aβ and tau are central to AD pathology. Our services include

Aβ42/Aβ40 Ratio Quantification
Tau Phosphorylation Assays
Detect p-tau181 and p-tau217 in brain tissue or biofluids.
Amyloid PET Imaging Correlates

Synaptic and Neuronal Injury Biomarkers

Synaptic loss is a key driver of cognitive decline. We analyze

Synaptophysin and SNAP-25
Quantify synaptic protein levels in brain homogenates or CSF.
Neurofilament Light Chain (NfL)

Neuroinflammation and Immune Biomarkers

Our assays include

Cytokine Profiling
Measure IL-6, TNF-α, and other inflammatory markers in brain tissue or biofluids.
TREM2 Signaling Analysis
Study microglial activation and phagocytosis in AD models.
TSPO PET Imaging Correlates
Link neuroinflammation to fluid biomarker changes.

Oxidative Stress and Metabolic Biomarkers

We evaluate

8-OHdG and Isoprostanes
Quantify oxidative damage in brain tissue or plasma.
Metabolomic Profiling
Identify metabolic shifts using mass spectrometry-based platforms.

Multi-Omics Integration

Combining multiple data layers enhances biomarker discovery. Our expertise includes

Proteomics and RNA Sequencing
Uncover novel biomarkers and pathways in AD models.
Machine Learning Analysis
Use AI-driven tools to identify biomarker panels and predict disease progression.

Applications in Drug Development

Therapeutic Efficacy Monitoring
Track Aβ clearance, tau reduction, or synaptic preservation in response to treatments.
Biomarker Panels for Preclinical Trials
Develop multi-analyte panels for robust efficacy and safety assessments.

Partner with Ace Therapeutics to unlock the power of biomarker discovery in your Alzheimer's research. Contact us to design a study tailored to your goals.

Frequently Asked Questions (FAQ)

Can you analyze biomarkers in CSF and plasma simultaneously?

Yes. We offer multi-analyte profiling in both biofluids to capture systemic and CNS-specific changes.

How do you validate novel biomarkers?

We use orthogonal methods (e.g., ELISA, Western blot, immunohistochemistry) and correlate findings with pathological and behavioral outcomes.

Do you offer machine learning for biomarker analysis?

Absolutely. Our AI-driven tools identify biomarker panels and predict disease progression with high accuracy.

Our products and services are for research use only and can not be used for diagnostic or other purposes.